Precigen Q1 loss narrows to $22.7M; raises $72.8M in offering; pipeline advances

PRECIGEN, INC.

2023-Q1 EPS reported -$0.10 revenue$1,851,000

Revenue fell 66% YoY; Q1 operating loss $22.7M ($0.10 EPS) vs $23.9M ($0.12 EPS) in Q1 2022.
Cash, equivalents and investments $125.4M; net proceeds of $72.8M from public offering at $1.75/share.
Retired $29.5M of convertible notes; remaining $13.8M due July 2023 to be retired with restricted cash.
Phase 1 PRGN-2012 data: 50% complete response; Phase 2 enrollment completed (N=23).
First patient dosed with PRGN-3007 UltraCAR-T (PD-1 checkpoint); regained exclusive rights to CD19 and BCMA targets.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECIGEN, INC. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 10, 2023, reporting its financial results for the quarter ended March 31, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-23-007072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.